Federal Circuit Court Begins Lilly’s 340B Contract Pharmacy Lawsuit Appeal in Earnest

Courtroom interior of the USCA Seventh Circuit
The U.S. Seventh Circuit Court of Appeals issued a schedule for the filing of briefs in Lilly's 340B contract pharmacy lawsuit.

A federal appeals court in Chicago is satisfied with the final judgement it ordered a lower court to issue in Lilly’s 340B contract pharmacy lawsuit, clearing the way the lawsuit’s next stage to get rolling.

The U.S. Seventh Court of

Read More »

Influential HIV/AIDS Group Asks Gilead to Exempt Ryan White Clinics from Company’s 340B Contract Pharmacy Restrictions

Gilead exterior office sign
Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies wholly owned by covered entities.

Ryan White Clinics for 340B Access (RWC-340B) has asked drug manufacturer Gilead to exempt all Ryan White clinics from the company’s conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

RWC-340B made the

Read More »

73 Groups Want Congress to Enact Major Drug Pricing Reforms by Memorial Day

Push for Lower Rx Prices organization wordmark
Seventy three organizations, under the banner Push for LowerRx Prices, launched a campaign to press Congress to pass comprehensive Democratic drug pricing legislation by Memorial Day.

More than 70 groups representing patients, healthcare professionals, consumers, retirees, employers, and unions launched a campaign this morning to get comprehensive Democratic drug pricing legislation signed into law by Memorial Day.

It is premature to guess how the final version

Read More »

Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block access

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

health care workers in hazmat suits with COVID-19 patient
Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.

April 14

Read More »

340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds

bottles of drugs on pharmacy shelves
Avalere Health says it found that 340B DSH hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations.

340B disproportionate share (DSH) hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations, according to a new study.

Healthcare consulting firm Avalere Health

Read More »

JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly

New research in JAMA Internal Medicine says many NCI-designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially." 340B groups point out that the rates are negotiated and they need the revenue for their safety net mission.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine. Hospital groups have pointed

Read More »

Harvard Drug Policy Experts Write in JAMA About How Congress Could Fix 340B Contract Pharmacy Mess

screenshot of 340B drug pricing program article in JAMA
"Contract pharmacy restrictions are the latest problem with implementation of the 340B program that threaten to undermine its laudable goals," three Harvard drug policy experts say in an opinion article in JAMA.

A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.

“First, Congress could explicitly allow the participation of

Read More »

At Direction of U.S. Appeals Court, Judge Issues Amended Judgement in Lilly’s 340B Contract Pharmacy Case

Senior District Court Judge Sarah Evans Barker
It is unknown whether U.S. Senior District Judge Sarah Evans Barker’s amended partial final judgement in Lilly's 340B contract pharmacy lawsuit will satisfy a higher court that kicked the case back to her.

A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit. It is not clear whether the judge did enough to satisfy

Read More »

Sanofi Makes Two Big Changes to its 340B Contract Pharmacy Policy

Sanofi outdoor building sign
Changes to Sanofi's 340B drug pricing conditions may eliminate 340B discounts for health centers using multiple contract pharmacies within a chain.

Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms. One is raising flags among 340B providers and the other appears to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report